8th ESO-ESMO Arab and Southern European Countries Masterclass in Clinical Oncology
30 ESCO credits
23.01.2020 - 27.01.2020
Limassol, Cyprus
MASTERCLASS
Description
Chairs: M.S. Aapro, CH - N. Pavlidis, GR
Co-chairs: J. Gligorov, FR - S. Khatib, JO
Host Chair: D. Papamichael, CY
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical and clinical oncologists who wish to improve their skills in the management of cancer patients.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-orientated training. The programme focuses on breast, gynaecological, lung, urological and gastrointestinal cancers. Spotlight sessions will facilitate compact update on head and neck, melanoma, elderly patients, soft tissue sarcoma, non-Hodgkin lymphoma cancer of unknown primary, supportive care and the role of informal supporter.
TEACHING FORMAT
The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited. Participants will deliver case presentations within tumour boards and discuss them with the chairs and the faculty.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.
THE MASTERCLASS IS:
• Full immersion
• 3-and-a-half-day residential event
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on breast, gynaecological, lung, urological and gastrointestinal cancers.
Held under the auspices of the | |||
![]() |
![]() |
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Faculty
FACULTY
M.S. Aapro, Clinique de Genolier, CH
H. Azim, Cairo University, Cairo Oncology Center, EG
H. Azim jr, American University of Beirut, LB
M.J. Cardoso, Champalimaud Foundation, Lisbon, PT
S. Cascinu, Università di Modena e Reggio Emilia, Modena, IT
G. Ceresoli, Humanitas Gavazzeni, Bergamo, IT
A. Charalambous, Cyprus University of Technology, Limassol, CY
A. Constantinidou, University of Cyprus, Medical School, Nicosia, CY
A. Eniu, Cancer Institute « I. Chiricuta”, Cluj-Napoca, RO
F. Geara, American University of Beirut, LB
H. Gogas, University of Athens, Athens, GR
J. Gligorov, APHP Tenon, IUC-UPMC, Sorbonne University, Paris, FR
J. Khader, King Hussein Cancer Center, Amman, JO
P. Kountourakis, Bank of Cyprus Oncology Centre, Nicosia, CY
N. Mottet, University Jean Monnet, Saint Etienne, FR
R. Orecchia, European Institute of Oncology, Milan, IT
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY
N. Pavlidis, Ioannina School of Medicine, GR
G. Pruneri, European Institute of Oncology, Milan, IT
J. Remon-Masip, Centro Integral Oncología Clara Campal (CIOCC), Barcelona, ES
A. Stathis, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
S. Temraz, American University of Beirut, LB
J.B. Vermorken, Antwerp University Hospital, BE
General information
ORGANISING SECRETARIAT
European School of Oncology
Dolores Knupfer
Piazza Indipendenza 2
6500 Bellinzona
Switzerland
Ph +41 91 820 0951 or 52, Fx +41 91 820 0953
Email: dknupfer@eso.net
Applications:
Alice Ciocchini, aciocchini@eso.net, ph +39 02 85464529
TRAVEL SUPPORT
Travel support will be made available as a contribution to travel expenses, to admitted participants coming from lower-middle- income countries as defined by the World Bank.
CERTIFICATE OF ATTENDANCE
Participants will receive their certificate of attendance via e-mail after the event on completion of the evaluation form.
The programme is furthermore accredited with 25 ESMO-MORA category 1 points.
Application
IDEAL MASTERCLASS CANDIDATE
• Age below 40 years
• At least 2-3 years’ experience in medical or clinical oncology
• Involvement in scientific activities (preferable)
• Intermediate level of English
Priority will be given to suitable applicants working in Arab and Southern European countries.
Participants will be asked to bring their personal laptop or tablet (wireless enabled) to the Masterclass as an event-dedicated website will be created and all questionnaires and certificates will be accessible only from there.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (30 JUNE 2019)
Programme
23 January
Participants’ arrival and dinner |
24 January
8:00 | Registration | |
8:45 | Welcome address M.S. Aapro, CH - N. Pavlidis, GR |
|
UROLOGICAL CANCERS SESSION Chairs: J. Khader, JO - N. Mottet, FR |
||
9:00 | Management including active surveillance of localized prostate cancer J. Khader, JO |
|
9:25 | Discussion | |
9:30 | Key topics in locally advanced, advanced and metastatic prostate cancer N. Mottet, FR |
|
9:55 | Discussion | |
10:00 | Update in the management of bladder cancer J. Khader, JO |
|
10:25 | Discussion | |
10:30 | Coffee break | |
11:00 | Update in the management of renal cancer N. Mottet, FR |
|
11:25 | Discussion | |
11:30 | Management of relapsed testicular cancer S. Temraz, LB |
|
12:00 | Urological Cancers Tumor Board (4 cases) | |
13:00 | Lunch break |
|
LUNG CANCER SESSION Chairs: G. Ceresoli, IT - F. Geara, LB |
||
14:00 | The impact of radiation therapy in lung cancer F. Geara, LB |
|
14:25 | Discussion | |
14:30 | Neoadjuvant and adjuvant systemic treatment in NSCLC G. Ceresoli, IT |
|
14:55 | Discussion | |
15:00 | Systemic chemotherapy and targeted treatment in metastatic NSCLC J. Remon-Masip, ES |
|
15:25 | Discussion | |
15:30 | Coffee break | |
16:00 | Immune check point inhibitors in NSCLC J. Remon-Masip, ES |
|
16:25 | Discussion | |
16:30 | Systemic therapy of small-cell lung cancer G. Ceresoli, IT |
|
16:55 | Discussion | |
17:00 | Systemic management of advanced mesothelioma G. Ceresoli, IT |
|
17:25 | Discussion | |
17:30 | Lung Cancer Tumor Board (4 cases) | |
20:00 | Dinner |
25 January
GASTROINTESTINAL CANCERS SESSION Chairs: P. Kountourakis CY – S. Cascinu, IT |
||
8:30 | Adjuvant / neoadjuvant systemic treatment in colorectal cancer P. Kountourakis CY |
|
8:55 | Discussion |
|
9:00 | Systemic treatment in advanced colon cancer S. Cascinu, IT |
|
9:25 | Discussion |
|
9:30 | Radiation treatment in rectal cancer J. Khader, JO |
|
9:55 | Discussion |
|
10:00 | Systemic treatment in early and advanced gastric cancer S. Cascinu, IT |
|
10:25 | Discussion |
|
10:30 | Coffee break |
|
11:00 | Gastrointestinal Cancers Tumor Board (4 cases) |
|
12:00 | Lunch | |
SPOTLIGHT SESSION 1 |
||
13:00 | Modern management of melanoma H. Gogas, GR |
|
13:25 | Discussion | |
13:30 | Cancer of unknown primary N. Pavlidis, GR |
|
13:55 | Discussion | |
14:00 | How do I manage cancer in elderly patients M.S. Aapro, CH |
|
14:25 | Discussion | |
14:30 | The role of informal supporter A. Charalambous, CY |
|
14:50 | Discussion | |
15:00 | Update in the management of high-grade NHL A. Stathis, CH |
|
15:25 | Discussion | |
15:30 | Coffee break | |
16:00 | Parallel Group Sessions I (Cases discussion in three groups) |
26 January
BREAST CANCER SESSION Chairs: J. Gligorov, FR - H. Azim, EG |
||
8:30 | What the clinician needs to know from the breast pathologist G. Pruneri, IT |
|
8:55 | Discussion | |
9:00 | Current controversies/challenges in breast surgery M.J. Cardoso, PT |
|
9:25 | Discussion | |
9:30 | The role of radiotherapy in e arly and locally advancedbreast cancer R. Orecchia, IT |
|
9:55 | Discussion | |
10:00 | Genomic testing in breast cancer H. Azim jr, LB |
|
10:25 | Discussion | |
10:30 | Coffee Break | |
11:00 | Neoadjuvant/adjuvant chemotherapy and biological agents A. Eniu, RO |
|
11:25 | Discussion | |
11:30 | Neoadjuvant/adjuvant endocrine therapy J. Gligorov, FR |
|
11:55 | Discussion | |
12:00 | Management of HER2+ advanced breast cancer A. Eniu, RO |
|
12:25 | Discussion | |
12:30 | Management of triple-negative advanced breast cancer H. Azim, EG |
|
12:55 | Discussion | |
13:00 | Management of ER+ advanced breast cancer J. Gligorov, FR |
|
13:25 | Discussion | |
13:30 | Lunch Break |
|
14:30 | Breast Cancer Tumor Board (4 cases) | |
SPOTLIGHT SESSION 2 | ||
15:30 | Supportive care M.S. Aapro, CH |
|
15:55 | Discussion | |
16:00 | Update in the management of soft tissue sarcomas A. Constantinidou, CY |
|
16:25 | Discussion | |
16:30 | Coffee break | |
17:00 | Parallel Group Sessions II (Case discussion in three groups) |
27 January
GYNECOLOGICAL CANCER SESSION Chairs: A. Constantinidou, CY - J.B. Vermorken, BE |
||
8:00 | Systemic management of ovarian cancer J.B. Vermorken, BE |
|
8:25 | Discussion | |
8:30 | Systemic management of locally advanced or metastatic cervical and endometrial cancer J.B. Vermorken, BE |
|
8:55 | Discussion | |
9:00 | Gynecological Cancers Tumor Board (4 cases) | |
10:00 | Coffee break | |
SPOTLIGHT SESSION 3 |
||
10:30 | Update in the management of head and neck cancer J.B. Vermorken, BE |
|
10:55 | Discussion | |
11:00 | Learning self-assessment test |
|
11:45 | Closing remarks amd awards |